Welcome to our dedicated page for Iteos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on Iteos Therapeutics stock.
iTeos Therapeutics news covers the former clinical-stage biopharmaceutical company's immuno-oncology pipeline, including programs aimed at tumor immunology and immunosuppressive pathways such as the TIGIT/CD226 axis and the adenosine pathway. Recurring updates include clinical data for belrestotug combinations, EOS-984, EOS-215 and other preclinical programs, financial results, conference presentations and collaboration developments.
Recent company developments also include the termination of the belrestotug development program, a strategic review and wind-down of operations, and completed corporate-status changes tied to the acquisition of the company's common stock, Nasdaq delisting and Exchange Act deregistration.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) reported positive results for the belrestotug + dostarlimab combination in lung cancer, completed successful enrollment in head and neck cancer trials, and raised $120 million in a direct offering. The company's cash balance of $715 million as of May 10, 2024, is expected to fund operations through 2027.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced a $120 million Registered Direct Offering led by existing investors RA Capital Management and Boxer Capital. The purchase price of $17.50 per share represents a premium of approximately 44% to the last close. This offering strengthens the company's balance sheet, increasing the pro forma cash position to $715 million, extending anticipated runway through 2027.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.